Drug Type Mesenchymal stem cell therapy |
Synonyms Adiposederived mesenchymal progenitor cell therapy Cellular Biomedicine Group, Autologous haMPC therapy Cellular Biomedicine Group, Re-Join + [1] |
Target- |
Mechanism Cell replacements |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Phase 2 | 30 | BDDE cross-linked sodium hyaluronate gel+Human adipose-derived mesenchymal progenitor cells | uazbapikyq(njevxeuyli) = No serious AEs were observed in this study. lyhlownvpn (kuhvxichlg ) | Positive | 01 Jan 2020 | ||
Phase 2 | 53 | oxuyzxlzhy(oenjcndpwa) = Compared with the HA group, significantly more patients achieved 50% improvement of WOMAC and a trend of more patients achieved a 70% improvement rate in Re-Join® group agrvusfzur (khkullsser ) View more | Positive | 21 May 2019 | |||